Latest News

Home breadcrumb arrow Latest News

Press Release – Axalbion to Present Promising Phase 2 Clinical Data in Chronic Cough with AX-8, a Novel TRPM8 Agonist, in an Oral Presentation at the American Thoracic Society (ATS) 2023 International Conference

March 21, 2023

Proof-of-Concept Study Signals AX-8’s Potential in Chronic Cough Treatment, Especially in Patients with Moderate-to-Severe Throat Discomfort

Read more

Press Release – Axalbion Announces Positive Findings from Phase 2 Clinical Study in Chronic Cough with AX-8, a Novel TRPM8 Agonist

June 29, 2022

AX-8 reduces cough frequency and improves patient-reported outcomes in patients with chronic cough

Read more

Press Release – Axalbion Announces First Patients Treated in Phase 2 Clinical Trial in Chronic Cough with AX-8, a Novel TRPM8 Agonist

October 20, 2021

TRPM8 Pathway May Play Antitussive and Counterirritant Role in Chronic Cough; Data Expected Mid 2022

Read more

Axalbion will start a proof of concept study in patients with chronic cough

May 6, 2021

Axalbion will soon start recruitment for a Phase 2 study to assess the efficacy and safety of AX-8 in patients with chronic cough.

Read more

Welcome to Axalbion Therapeutics Limited

April 15, 2021

Axalbion therapeutics Limited, Axalbion SA's parent company, has been incorporated in UK, 24 February 2021.

Read more

Dr. Michael Kitt was appointed CEO of Axalbion

February 6, 2020

Dr. Kitt joined Axalbion as Chief Executive Officer in November 2019, bringing more than 30 years of clinical development experience and industry expertise.

Read more

Results of an exploratory study in refractory chronic cough patients suggest that AX-8 reduces awake cough frequency

June 27, 2019

Results of the AX8-001 study (EudraCT no. 2017-003108-27) titled "A PILOT STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF AX-8 FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH" are available on EU Clinical Trials Register:

Read more

Welcome to Axalbion’s new website

June 20, 2019

If you need further information please feel free to contact us.

Read more